The Potency of Biomarkers for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease
Neurodegenerative diseases (NDs) are a range of neurologic conditions associated with neuron death, mostly with no effective treatment. The early and accurate diagnosis of NDs is very important. Late and/or inaccurate diagnosis of NDs leads to making a mistake in treatment and increasing the patient’s cost. The clinical challenge of NDs includes the inability to make a definitive diagnosis in the early stages of the disease and difficulties in predicting disease progression. In recent years, several attempts have been made to identify and confirm the biomarkers of NDs, including genetic, biofluid, and imaging-based variants. Most often employed genetic biomarkers are genetic mutations that induce a specific neurological illness. DNA and RNA biomarkers are associated with detecting familial forms of NDs. Blood and cerebrospinal fluid indicators are commonly utilized to diagnose NDs. It is noteworthy that imaging-based biomarkers have made significant advances and can be enormously useful for early diagnosis.
Choosing several suitable biomarkers concurrently in pharmaceutical research and clinical trials for NDs help to accelerate the identification and evaluation of treatment efficacy in NDs. The present study has focused on the types and applications of biomarkers in Alzheimer's disease and Parkinson's disease.
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.